LYEL vs V · rev $6.0K vs P/E 33, rev $40.00B
Lyell Immunopharma Inc (LYEL) versus Visa Inc. Class A (V) — a side-by-side from cached financials, not a winner call.
Lyell Immunopharma Inc (LYEL) is a biotechnology company listed on US.
Visa Inc. Class A (V) is a credit services company listed on US. It is led by Ryan McInerney.
Latest reported LYEL revenue for 2026-06-30 was $6.0K. Net income was -$68.9M. LYEL currently screens at market cap $143.5M.
Latest reported V revenue for 2025-09-30 was $40.00B. Net income was $20.06B. V currently screens at market cap $659.78B and trailing P/E 33.5.
LYEL currently screens at market cap $143.5M. V currently screens at market cap $659.78B and trailing P/E 33.5.
Not investment advice. Open the LYEL and V stock pages for the full models.
Not investment advice.